SELECT trial: semaglutide and cardiovascular outcomes

StudyGovernment health research

Source type: Study
Access type: Abstract/index
Publisher: PubMed
Indexed by: PubMed
Date: 2023
Added: 2026-06-19

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

Government health research

Publisher type: Government research
Bias profile: Low

This source is strongest for safety and clinical outcomes and weaker for consumer context and regulatory status.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 66/100; Context Source
Clinical outcomes: 90/100; Primary Anchor
Mechanism: 90/100; Primary Anchor
Safety: 92/100; Primary Anchor
Consumer context: 88/100; Strong Support
Trial discovery: 89/100; Strong Support

Best used for

Research synthesis
Public-health context
Safety resources

Weak for

Primary endpoint extraction when a study is available

Used in Viral Vitalism

Primary sourcesignal2 references

GLP-1s Are Not Just a Weight Loss Story

Roles: Primary source

Show section-level references

Primary sourcestudy1 reference

Semaglutide and cardiovascular outcomes in obesity without diabetes

Roles: Primary source

Show section-level references

SELECT

Claim ledger

Claims supported

Reviewed claim cards that cite this source in the evidence graph.

supported84/100

semaglutide: Semaglutide reduced major adverse cardiovascular events in SELECT participants

Semaglutide reduced major adverse cardiovascular events in SELECT participants with overweight or obesity and established cardiovascular disease without diabetes.

Strong human evidence3 sources